Eisai/Biogen’s Alzheimer’s Drug Finally Closing In On EU Approval

 
• By Andrew McConaghie
  
The European Medicines Agency's building in Amsterdam
The EMA's review has taken more than two years, with safety and efficacy concerns now overcome. • Source: Alamy

More from New Products

More from Neurological